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ABSTRACT
Tobacco smoking is a risk factor for variety of cardio-vascular diseases, such as hypertension, myocardial infarction, stroke and many 
others. It is of great importance for hypertensive patients to stop smoking. One of the medicines widely used for smoking cessation 
in Bulgaria is the original Bulgarian product Tabex®, which is developed on the basis of natural plant alkaloid cytisine. The aim of the 
following study was to ivestigate the effects of cytisine on some brain and hepatic biochemical parameters in spontaneously hyper-
tensive rats (SHR), an widely used rodent model for human essential hypertension, and to compare the obtained results with their 
age-matched normotensive controls Wistar Kyoto (WKY). Multiple cytisine administration did not affect the activity of ethylmorphine-
N-demethylase (EMND) and anylinehydroxylase (AH), as well as the quantity of cytochrome P 450, nor in WKY neither in SHR In the liver 
cytisine increased the MDA quantity both in SHR and in WKY, by 25% (p<0.05) and by 29% (p<0.05) respectively, while the GSH level 
was not significantly changed by the compound in both strains. In contrast, on the brain level, cytisine administration to SHR caused 
more prominent toxicity, resulted in GSH depletion and increased MDA quantity, while in WKY strain did not exert any toxicity. Cytisine 
did not significantly affect ALAT and ASAT activity in both strains. In conclusion, the results of our study suggest higher brain toxicity 
of cytisine in spontaneously hypertensive rats, that might be due to their pathophysiological characteristics. 
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cytisine. Cytisine is an alkaloid from the plant Laburnum 
anagyroides Med., (Cytisus laburnum L., Fabaceae) which 
if widely distributed in the Sought part of Central and 
Eastern Europe. All parts of this plant contain the alka-
loid cytisine, but the largest quantity (up to 3%) is found 
in seeds. (T zankova and Danchev , 2007). In Bulgaria, 
cytisine, as a smoking cessation aid, has been used since 
the 1960s and has been manufactured and marketed since 
1964 as Tabex® (Sopharma, Bulgaria).
Taking into consideration a number of hypertensive 
patients who smoke and the necessity to stop this vice, 
paucity of available data on drug metabolism and drug 
toxicity of cytisine on this pathological state, it is impor-
tant to characterize the effects of cytisine on some liver 
and brain biochemical parameters in spontaneously 
hypertensive rats. SHRs are a suitable model for investiga-
tion not only of the cardio-vascular diseases, but also of 
drug metabolism and drug toxicity in this pathological 
condition. At the same time, it is well known that SHRs 
are more prone to liver and brain injury, provoked by 
some compounds.
The aim of the following study was to investigate the 
effects of cytisine, administered to SHR for 14 days on 
some brain and hepatic biochemical parameters. 
Introduction
According to the World Health Organisation, one third 
of the adult population smokes. Epidemiological data 
show that tobacco smoking provokes many diseases in 
cardio-vascular, pulmonary and other systems and it is 
one of the major causes for premature death in the world. 
Tobacco may aggravate the hypertensive state in patients 
with cardio-vascular diseases. That is why smoking 
cessation is obligatory condition for them. Because of 
the great importance of tobacco dependence, there are 
many approaches to resolve this problem. The current 
most effective method for treatment of nicotine addiction 
is nicotine replacement therapy. In Bulgaria, the most 
used method is the therapy with the original Bulgarian 
drug Tabex®. The product is developed on the basis of 
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Materials and methods
Reagents and chemicals
All reagents used were of analytical grade. Cytisine was 
provided by Sopharma Pharmaceuticals, Sofia, Bulgaria. 
The other chemicals: NaHCO3, KH2PO4, Trichloracetic 
acid, 2-Thyobarbituric acid, CH3COOH, Glucoso-6- 
phosphate, Semicarbazide, Nicotinamide, Ba(OH)2, 
ZnSO4, Ethylmorphine, Anyline, Na2S2O5, NADP, Phenol 
were purchased form Sigma Chemical Co. (Germany). 
2,2`-dinitro-5,5`dithiodibenzoic acid (DTNB), K2HPO4 
and NaH2PO4 × 2H2O  w e r e  o b t a i n e d  f r o m  M E R C K  
(Germany).
For the aim of the experiments, cytisine was dissolved 
ex tempore in distilled water in quantity for receiving 
working solutions. The solutions were administered once 
daily via stomach tube (1ml/100 g b.w.). 
Animals
Experiments were performed in 12 male SHR (body 
weight 180–230 g) and 12 WKY (body weight 200–250 g), 
obtained from Charles River Laboratories (Sulzfeld, 
Germany). The animals were housed in Plexiglas cages (3 
per cage) at 20±2 °C and 12-h light : 12-h dark cycle. Food 
and water were provided ad libitum. 
Blood pressure was measured in conscious animals 
using a semi-automated tail-cuff device (LE5002, Letica 
S/A, Spain). Before the experimental period, the rats 
were conditioned to the restraining cylinders and blood 
pressure measurement. Rats were pre-warmed for 10 min 
using a temperature – controlled warming holder (37 °C) 
to facilitate tail blood flow before their blood pressure 
was measured. The mean of tree tail-cuff readings was 
used as the systolic and diastolic blood pressure value. 
Body weight and organ weight (livers and brains) were 
measured with a standard laboratory scale.
All procedures were approved by the Institutional 
Animal Care Committee and performed strictly follow-
ing the principles stated in the European Convention 
for the Protection of Vertebrate Animals used for 
Experimental and other Scientific Purposes (ETS 123) 
(1991).
Design of the experiment
The animals were divided into four groups (n=6 each). 
The first group was SHR receiving cytisine at dose 5 
mg/kg (Tabex. Product monograph, Sopharma, 2006) 
p.o., once daily for 14 days. The second group was WKY, 
receiving cytisine 5 mg/kg po once a day for 14 days. The 
third and fourth groups included respective controls, 
untreated animals from two rat strains, which were 
involved in the experiment from the very beginning and 
housed under the same standard laboratory conditions as 
treated animals.
All animals were fasted overnight before euthanasia. 
24 hours after the last administered dose of cytisine, 
the animals of all groups was weighed, euthanized by 
decapitation and blood, livers and brains were taken for 
biochemical assessment.
Preparation of liver microsomes for biochemical 
assay (Guengerich, 1987) 
Rats were decapitated and the livers were excised, 
perfused with 0.15 M KCl and minced. The latter was 
homogenized with 3 volumes of 1.17% KCl solution in 
a glass homogenizer. The liver homogenates were then 
centrifugated at 10,000 × g for 30 min. The supernatant 
fractions were centrifugated at 105,000 × g for 60 min. 
The resulting microsomal pellets were stored at –20  °C 
until assayed. 
Evaluation of Phase I of biotransformation
Assay of aniline 4-hydroxilase activity (Cohen et al., 2000)
4-hydroxilation of aniline to 4-aminophenol, that is 
chemically converted to a phenol-indophenol complex 
with an absorption maximum at 630 nm. Enzyme activity 
is expressed as nmol/min/mg.
Assay of EMND activity (Cohen et al., 2000) 
The enzyme activity was evaluated by the formation of 
formaldehyde, trapped in the solution as semicarbazone 
and measured by the colorimetric procedure of Nash, at 
415 nm. Enzyme activity is expressed as nmol/min/mg.
Assessment of cytochrome P450 quantity (Omura and Sato, 1964) 
At the day of assay the microsomal pellets were resus-
pended and diluted in phosphate buffer + EDTA (pH=7.4). 
Liver protein concentration was mesured, using the 
method of Lowry (1951) and was adjusted to 10 mg/ml. 
Cyt P450 quantity was quantified spectrophotometrically 
as a complex with CO, at 450 nm
Preparation of brain and liver homogenate for 
MDA assessment (Deby and Goutier, 1990)
Samples of liver and brain tissue were homogenized in 
25% trichloracetic acid (TCA) and 0.67% thiobarbituric 
acid (TBA) in Glass homogenizer (PX-OX 2000). The 
samples were then mixed thoroughly, heated for 20 min in 
a boiling water bath, cooled and centrifuged at 4,000 rpm 
for 20 min. The absorbance of supernatant was measured 
at 535 nm against a blank that contained all the reagents 
except the tissue homogenate. MDA level was expressed 
as nmol/g wet tissue.
Preparation of brain and liver homogenate 
for GSH assessment (Fau et al., 1994)
Samples of liver and brain tissue were homogenated in 5% 
trichloracetic acid (TCA) in Glass homogenizer (PX-OX 
2000) and centrifugated for 20 minutes at 4,000 rpm. 
GSH was assessed by measuring non-protein sulfhy-
dryls after precipitation of proteins with TCA, followed 
by measurement of thiols in the supernatant by the DTNB 
reagent (Bump et al., 1983). GSH level was expressed as 
nmol/g wet tissue.
Evaluation of transaminase activity (ALAT and ASAT) in serum
The blood was taken into a tube containing EGTA. Serum 
was separated by centrifugation in bench centrifuge 23
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(Eppendorf, MiniPlus) at 10,000 rpm for 10 min, 4 °C and 
serum activity of aspartate aminotransferase (ASAT) and 
alanine aminotransferase (ALAT), were measured using 
automated, optimized spectrophotometrical method 
(COBOS Integra 400 plus, Roche Diagnostics).
Statistical analysis
The results were presented as ± SD of 6 animals in each 
group. Student’s t-test was used. Probability values less 
than 0.05 were considered significant.
Results
Eff  ect of cytisine on P 450 quantity and enzyme activities (Table 1).
Untreated SHRs presented higher (p<0.05) activity of 
EMND than untreated WKY. Cytisine treatment did 
not affect the activity of EMND and AH, as well as the 
quantity of P 450, nor in WKY neither in SHR. 
Eff  ect of cytisine on hepatic GSH and MDA levels (Table 2)
Untreated SHRs showed lower (by 26% (p<0.05) GSH level 
and higher (by 38% (p<0.05) MDA quantity than WKY 
untreated group. Cytisine increased the MDA quantity 
both in SHR and in WKY, by 25% (p<0.05) and by 29% 
(p<0.05) respectively, while the GSH level was not signifi-
cantly changed by the compound in both strains. 
Eff  ect of cytisine on brain GSH and MDA levels (Table 3)
Brains from control SHR group displayed lower GSH level 
by 30% (p<0.05) and higher MDA level by 25% (p<0.05), 
compared to the control WKY group. In brain homogenate 
from SHR, cytisine decreased GSH level by 25% (p<0.05) 
and increased MDA quantity by 22% (p<0.05). The results 
were compared to the unntreated SHRs. Cytisine did not 
change these parameters in WKY.
Eff  ect of cytisine on transaminases (Table 4)
Cytisine did not affect significantly ALAT and ASAT 
activity in both strains. 
Discussion
Cytisine, a natural plant alkaloid, has been used in 
Bulgaria for 40 years in the clinical management of smok-
ing cessation and has shown similar to nicotine pharma-
cological characteristics. Being a competitive blocker of 
α4β2* nAChRs, cytisine behaves as an antagonist in the 
presence of nicotine and therefore would decrease craving 
and attenuate nicotine withdrawal symptoms in humans 
(Lukas, 2006).
Cytisine is considered to be efficient and safe drug 
for smoking cessation (Etter, 2008). However there is not 
sufficient clinical experience with Tabex® in patients with 
chronic diseases, like hypertension, diabetes etc.
Regarding the lack of experimental data about 
cytisine metabolism and toxicity, in the present study, 
Table 1. Effect of cytisine on cytochrome P450 quantity, AH and EMND 
activity after multiple administration in male SHR, compared to male 
WKY.
WKY SHR
Parameter Control Cytisine Control Cytisine
P-450 quantity 
(nmol/mg) 0.336 ± 0.002 0.356 ± 0.004 0.365 ± 0.01 0.350 ± 0.009
AH activity 
(nmol/mg/min) 0.043 ± 0.002 0.044 ± 0.003 0.041 ± 0.004 0.036 ± 0.005
EMND activity 
(nmol/mg/min) 0.332 ± 0.007 0.305 ± 0.011 0.472 ± 0.04* 0.511 ± 0.02
Data are expressed as mean ± SD of 6 rats, * p<0.05 vs control WKY
Table 2. Effect of cytisine multiple administrations on hepatic GSH level 
and MDA quantity in male SHR, compared to male WKY.
WKY SHR
Parameter Control Cytisine Control Cytisine
GSH 
(nmol/g) 6.34 ± 0.16 5.74 ± 0.16 4.69 ± 0.14* 4.47 ± 0.16
MDA 
(nmol/g) 1.05 ± 0.03 1.35 ± 0.11* 1.45 ± 0.04* 1.81 ± 0.12+
Data are expressed as mean ± SD of 6 rats, 
* p<0.05 vs control WKY; +p<0.05 vs control SHR
Table 3. Effect of cytisine multiple administrations on brain GSH level 
and MDA quantity in male SHR, compared to male WKY.
WKY SHR
Parameter Control Cytisine Control Cytisine
GSH 
(nmol/g) 1.28 ± 0.03 1.16 ± 0.08 0.89 ± 0.05* 0.67 ± 0.07+
MDA 
(nmol/g) 3.89 ± 0.05 3.82 ± 0.09 4.86 ± 0.04* 5.95 ± 0.07+
Data are expressed as mean ± SD of 6 rats, 
* p<0.05 vs control WKY; +p<0.05 vs control SHR
Table 4. Effect of multiple administration of cytisine on serum ALAT and 
ASAT activity in male SHR, compared to male WKY.
WKY SHR
Parameter Control Cytisine Control Cytisine
ALAT 
UI/L 66.2 ± 6.2 61.3 ± 19.1 82.6 ± 4.2 92.7 ± 23.2
ASAT 
UI/L 234.2 ± 12.5 228.3 ± 9.3 329.3 ± 9.8* 289.2 ± 22.5
Data are expressed as mean ± SD of 6 rats, * p<0.05 vs control WKY 
we investigated the effect of cytisine on some hepatic 
and brain biochemical parameters, using spontaneously 
hypertensive rats (SHR), that are considered to be a suit-
able pathophysiological model for essential hypertension 
in human (Yoshimoto et al. 2003) 
Our results on the level of drug metabolizing enzyme 
systems reveiled higher EMND activity, marker of CYP 24
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3A (Amacher and Schomaker, 1998) in SHR with no dif-
ference in cytochrome P 450 quantity and AH activity, 
marker of CYP 2E1 (Monostory et al, 2004), compared 
to control WKY rats (Table 1). These results are in good 
correlation with the studies, carried out by Merrick et 
a. (1985) that showed a significant increase in EMND 
activity in SHR with only slight increases in cytochrome 
P450 quantity and AH activity, compared to WKY rats. 
Few years latter Basu et al. (1994) proved that this elevated 
CYP 3A activity in SHR is related to the augmentation of 
the arterial blood pressure. 
14 days oral administration of cytisine did not change 
the activity of EMND and the activity of AH, as well as 
the quantity of cytochrome P 450 nor in SHR, neither in 
WKY. These results are supported by data in the literature 
that discuss cytisine minimal hepatic biotransformation 
in humans and 90–95% excretion of the unchanged 
compound in the urine (Tabex. Product monograph, 
Sopharma, 2006). 
One of the essential factors for hypertension is the 
oxidative stress, which is characterized by low level of 
the intracellular protector GSH and high level of MDA, 
a product of lipid peroxidation and marker of oxidative 
stress. In their study Cediel et al. (2003) proved that in 
liver homogenates from SHR, MDA levels were higher and 
the ratio reduced/oxidized glutathione (GSH/GSSG) and 
glutathione peroxidase activity (GPx), were lower, com-
pare to WKY. Our results support these findings. Both 
in liver and brain the quantity of GSH was significantly 
lower and the MDA level was significantly higher in SHR, 
compared to the control WKY (Table 2 and 3). 
On the hepatic level, cytisine treatment did not affect 
the GSH quantity nor in SHR, neither in WKY, while 
the quantity of MDA was significantly increased in both 
strains. The lack of toxicity on GSH might be due to the 
lack of bioactivation of cytisine to metabolites that might 
conugate with GSH and cause its depletion. On the other 
hand, on the basis of our results we could suggest that 
the entire molecule of cytisine might have the ability to 
induce a process of lipid peroxidation, manifestated by the 
observed increase in MDA quantity. 
There are a number of in vivo studies on the potential 
hepatotoxic effect of cytisine in different animal species. 
The study of Angelova (1971) determined that chronic 
administration of cytisine to rats, at a dose of 1.35 mg/kg 
during 90 days caused a 2-fold increase in blood glutamate 
pyruvate transaminase (GPT) concentration, without 
significant changes in blood glutamic oxaloacetic trans-
ferase (GOT) and alkaline phosphatase. Such changes 
were not observed when cytisine was administered dur-
ing 45 days to mice (3.3 mg/kg) and 180 days to rats (0.45 
and 0.9 mg/kg) or dogs (0.46 mg/kg). In our experiment 
cytisine, administered orally 5 mg/kg for 14 days did not 
significantly change the values of serum transaminase 
activity, ASAT and ALAT, in any of the treated strains. 
These results might be due to the shorter period of admin-
istration (14 days) and to the large individual variations. 
On the brain level, multiple cytisine administration 
caused more prominent toxicity in SHRs, resulted in GSH 
depletion and increased MDA quantity, while in WKY 
strain did not exert any toxic effect. Reavill et al. (1990), 
in their studies in rats found out that cytisine crosses the 
blood-brain barrier less readily than nicotine. This might 
be one of the possible explanations for the observed 
lack of brain toxicity in WKY rats. On the other hand, 
it is proved that in chronic hypertension the blood brain 
barrier is characterised with an increased permeability 
due to disrupted tight junctions caused by endothelial 
dysfunctions (Lippoldt et al., 2000). The better perme-
ability of cytisine through the BBB in hypertensive rats, 
slower blood brain circulation in this state (Kishi et al., 
2004) could explain the higher brain toxicity of cytisine 
in hypertensive animals.
In conclusion, the results of our study suggest higher 
brain toxicity of cytisine in spontaneously hypertensive 
rats, that might be due to their pathophysiological 
characteristics. 
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